Depomed, Inc. (DEPO) Set to Announce Earnings on Tuesday
Depomed, Inc. (NASDAQ:DEPO) will be releasing its earnings data after the market closes on Tuesday, August 1st. Analysts expect Depomed to post earnings of $0.09 per share for the quarter.
Depomed (NASDAQ:DEPO) last issued its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.18. The business had revenue of $95 million for the quarter, compared to analysts’ expectations of $99.48 million. Depomed had a negative return on equity of 25.33% and a negative net margin of 21.41%. The business’s quarterly revenue was down 9.2% on a year-over-year basis. During the same period last year, the company posted $0.04 earnings per share. On average, analysts expect Depomed to post $-0.99 EPS for the current fiscal year and $-0.09 EPS for the next fiscal year.
Depomed, Inc. (NASDAQ:DEPO) opened at 10.51 on Tuesday. Depomed, Inc. has a 52 week low of $9.38 and a 52 week high of $27.02. The stock’s market capitalization is $655.20 million. The stock’s 50 day moving average price is $10.51 and its 200-day moving average price is $13.47.
In other Depomed news, insider Arthur J. Higgins purchased 15,000 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were purchased at an average price of $9.92 per share, for a total transaction of $148,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.59% of the company’s stock.
Several equities research analysts recently commented on the company. Mizuho dropped their target price on Depomed from $16.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, March 29th. Royal Bank Of Canada dropped their target price on Depomed from $22.00 to $19.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 29th. Cantor Fitzgerald reissued a “hold” rating and set a $19.00 target price on shares of Depomed in a report on Wednesday, March 29th. Janney Montgomery Scott reissued a “buy” rating and set a $26.00 target price on shares of Depomed in a report on Wednesday, March 29th. Finally, JMP Securities reissued an “outperform” rating and set a $16.00 target price (down previously from $30.00) on shares of Depomed in a report on Thursday, March 30th. Three analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $17.74.
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.